Palbociclib is an oral cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor that has been documented to slow breast cancer cell growth with estrogen receptors and can also work well with anti‐estrogen drugs [1]. Here, CDK4 is linked to breast carcinoma.